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Abstract  
Objective: To describe demographic and hormonal characteristics, co-morbidities (diabetes mellitus 
and hypertension), therapeutic procedures and their effectiveness, as well as predictors of morbidity 
and mortality in a nation-wide survey of Italian acromegalic patients. 
Design: Retrospective multicentre epidemiological study endorsed by the Italian Society of 
Endocrinology and performed in 24 tertiary referral Italian centres . The mean follow-up time was 120 
months. 
Results: A total of 1512 patients, 41% M, mean age: 45±13 years, mean GH: 31±37 mcg/L, IGF-I: 
744±318 ng/ml, were included. Diabetes mellitus was reported in 16% of cases, hypertension in 33%. 
Older age and higher IGF-I levels at diagnosis were significant predictors of diabetes and 
hypertension. At the last follow-up, 65% of patients had a controlled disease, of whom 55% were off 
medical therapy. Observed deaths were 61, with a standardized mortality ratio (SMR) of 1.13 (IC95%: 
0.87-1.46). Mortality was significantly higher in the patients with persistently active disease (1.93; 
IC95%: 1.34-2.70). Main causes of death were vascular diseases and malignancies with similar 
prevalence. A multivariate analysis showed that older age, higher GH at last follow-up, higher IGF-I 
levels at diagnosis, malignancy and radiotherapy were independent predictors of mortality. 
Conclusions. Pre-treatment IGF-I levels are important predictors of morbidity and mortality in 
acromegaly. The full hormonal control of the disease, nowadays reached in the majority of patients 
with modern management, reduces greatly the disease-related mortality. 
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Introduction 1 
Acromegaly is a serious and disfiguring rare disease, resulting from chronic exposure to elevated 2 
GH and IGF-I concentrations, mostly due to a pituitary GH-secreting adenoma. 3 
Almost all the epidemiological studies reported that acromegaly is associated with increased 4 
mortality with respect to the general population, mostly due to cardiovascular events and stroke 5 
(1-4). Some (1,5-7), but not all the surveys (8-11), also showed an increased mortality for 6 
respiratory complications, and even more controversial are the findings about increased mortality 7 
for cancer (4,12,13). 8 
Studies published between 1970 and 1995 reported standardized mortality ratio (SMR) of 1.89-9 
3.31, but more recent surveys showed SMR ranging from 1.16 to 2.14 (3,4). These data were 10 
interpreted to reflect an improvement of treatment modalities achieved over the years with the 11 
introduction of new drugs (2-4). Conventional external radiotherapy was found to decrease 12 
survival mostly in female patients according to some (7,9,11) but not all the studies (3,6,10). 13 
All the surveys agree that post-treatment GH levels are the strongest outcome predictor, (1,3,6-14 
11,13) but less agreement exists on the role of IGF-I concentrations either at diagnosis or after 15 
treatment (8-11,13,14). Since GH and IGF-I act on a wide range of biochemical pathways and 16 
modulate intermediate metabolism and cell growth, it is not surprising that acromegaly is a 17 
systemic disease, associated with a number of co-morbidities. Hypertension is reported to be 18 
present in 17% to 51% and diabetes mellitus in 9% to 23% of patients (15) contributing to 19 
increased mortality (5,12,13), whereas a better control of these associated conditions could 20 
increase survival (2). 21 
Thus, an increased mortality in acromegaly depends on several factors, some of which changed 22 
over the years. Due to the low prevalence of acromegaly, of about 60 patients per million 23 
inhabitants (15), only nation-wide surveys may produce significant data on patient outcome and 24 
predictive factors. This study presents epidemiological data on a large population of Italian 25 
acromegalic patients followed-up for more than 10 years, and includes mostly patients treated 26 
after the introduction of somatostatin analogs (SSAs). The survey has the following aims: 1) to 27 
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describe the demographic, clinical and hormonal characteristic of this well-defined acromegalic 28 
population, 2) to evaluate the kind of therapies preferred by Italian endocrinologists and their 29 
effectiveness, and 3) to assess the long-term outcome of the disease and what factors were 30 
predictive of morbidity and mortality. At the best of our knowledge, this is the first large–scale 31 
epidemiological study on acromegaly in Italy. 32 
 33 
Materials and methods 34 
Study design 35 
All the major endocrinological centres in Italy were invited to participate to the survey, that was 36 
endorsed by the Italian Society of Endocrinology. Twenty-four tertiary referral centers, most of 37 
which University Hospitals, accepted to participate to the study and collected clinical and 38 
biochemical data of all acromegalic patients who were proactively followed at the center. The 39 
number of patients from each centre ranged from 19 to 185 (Fig. 1). 40 
Inclusion criteria were age at diagnosis >18 years, Italian residence and diagnosis of acromegaly 41 
made between 1 January 1980 and 31 December 2002 according to standard biochemical criteria 42 
at the time of enrollment, with at least 1-year follow-up after diagnosis. Patients with GH 43 
hypersecretion due to ectopic GHRH secretion and Multiple Endocrine Neoplasia type 1 were 44 
excluded. The mean follow-up time from diagnosis to the end of the study was 120 months 45 
(median 90 months; IQR: 42-170 months).  Data were collected retrospectively by local 46 
investigators in a computerized database form developed using Access 2000 software (Microsoft 47 
Corporation 1999) and approved by all participants. Periodic meetings were organized in order to 48 
make the recording process as homogeneous as possible for all centres. All patients had given their 49 
informed consent to the collection of their data according to Ethic Committee indications of each 50 
centre. Patients' demographics, estimated date of appearance of typical clinical signs (i.e. change 51 
in shoes size, need to have rings enlarged and coarsening of facial features), pituitary imaging 52 
(tumor size and extension), hormonal data at baseline and during the follow-up period (serum GH 53 
levels; serum IGF-I levels; associated hyper-secretions, pituitary deficiencies) were collected for 54 
each patient. Diabetes mellitus and hypertension were investigated in order to study their impact 55 
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on mortality. Hypertension was diagnosed by the presence of systolic blood pressure ≥140 mm/Hg 56 
or diastolic blood pressure ≥90 mm/Hg or use of anti-hypertensive therapy. Diabetes mellitus was 57 
established on accepted international diagnostic criteria at the moment of diagnosis or use of 58 
specific drugs. In addition, the occurrence of cardio- and cerebro-vascular events and 59 
malignancies during follow-up were reported. After treatment, acromegalic disease was 60 
considered controlled when basal GH (mean of at least 3 samples) levels were below 2.5 mcg/L 61 
and/or nadir GH after an oral glucose load was less than 1 mcg/L and circulating IGF-I levels were 62 
normal according to an age adjusted normal range (16). The causes of death were obtained from  63 
death certificates or medical records. Data on mortality and sex- and age- adjusted distribution of 64 
diabetes and hypertension were then compared to those of the general Italian population using data 65 
reported by the Italian National Institute of Statistic (Health of All – Italia. Available at 66 
http://www.istat.it/sanita/Health), in year 2008 for mortality and 2005 for prevalence of co-67 
morbidities. 68 
 69 
Methods 70 
GH and IGF-I assays have changed over the years and were different among the participant 71 
centres. The IGF-I values were compared with an appropriate age-adjusted range and expressed 72 
also as Standard Deviation Score (SDS) using the following formula: (IGF-I value - 50th 73 
percentile)/(97th percentile-3rd percentile) divided by the corresponding z-score. Data 74 
collected at the end of nineties by the University of Genoa (Prof M Minuto and A Barreca) from 75 
more than 4000 Italian normal subjects of different regions, from 0 to 100 years, and including a 76 
minimum of 50 subjects for every 5 years of age, served as reference range (17). In particular, for 77 
the purpose of the present study, the following normal ranges (3° - 97° centiles) were used : 18-20 78 
years: 69-736 ng/ml;  21-25 years: 72-415 ng/ml; 26-30 years: 76-378 ng/ml; 31-35 years: 98-318 79 
ng/ml; 36-40 years: 60-280 ng/ml; 41-45 years: 77-260 ng/ml; 46-50 years: 68-286 ng/ml; 51-55 80 
years: 63-252 ng/ml; 55-60 years: 62-263 ng/ml; 61-65 years: 62-241 ng/ml; 66-70 years: 40-201 81 
ng/ml; 71-75 years: 41-217 ng/ml; 76-80 years: 29-269 ng/ml; 81-85 years: 25-264 ng/ml.  82 
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The choice to use a large unique Italian normative database, although offering some 83 
advantages, has self-evident important limitations due to variability of IGF-I reference 84 
ranges in the  many assays used in different centres over the years, and could constitute a 85 
bias.  86 
 87 
Statistical analysis 88 
Data were expressed as the mean ± SD and/or as the median and interquartile range (IQR 25-89 
75%), as appropriate. 90 
Prevalence of diabetes mellitus and hypertension in acromegalic patients was compared with data 91 
of the Italian population using direct standardization method and data reported by the Italian 92 
National Institute of Statistic in year 2005. Standardized rates along with 95% confidence interval, 93 
which was computed using the Armitage-Berry method, were reported. 94 
Mortality for all causes was compared with the mortality of the Italian population by means of the 95 
standardized mortality ratio (SMR), which is the ratio of the observed number of deaths in the 96 
study sample to the number of deaths expected according to a set of reference mortality rates, 97 
adjusted for age, sex and calendar year. A SMR greater than 1 means a higher mortality than 98 
expected in the reference population. Finally, exact Poisson 95% confidence intervals were 99 
calculated. 100 
The individual effect of demographic and clinical variables on the risk of developing diabetes 101 
mellitus, hypertension and mortality was evaluated by a logistic regression model. Univariate 102 
estimates of the Odds Ratios were presented along with their lower and upper 95% confidence 103 
intervals. Lastly, a multivariate model was built using backward selection including all variable 104 
found to be significant on univariate analysis. Interactions among variables were also checked. 105 
Model evaluation was carried out using a graphical examination of the residual diagnostics. 106 
Analyses were performed using R version 2.11. 107 
 108 
Results 109 
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Population at baseline 110 
A total of 1512 patients, 624 (41.2%) men and 888 (58.8%) women, were included into the study. 111 
The mean age at the time of diagnosis was 45 ± 13 years (median 46 years; IQR 36-54 years). 112 
Male patients were significantly younger than female patients (43 ± 13 vs 47 ± 13 years, P <0.001) 113 
(Fig. 2). Seventy percent of patients were diagnosed between 1990 and 2002. 114 
Estimated duration of the disease prior to diagnosis was 74 months (median 60 months; IQR 36-115 
96) without significant differences between the two genders. 116 
Radiological imaging revealed a micro-adenoma in 30% and a macro-adenoma in 70% of 117 
available cases, respectively. The latter was intrasellar in 44% of cases. Tumor size and extension 118 
were missing in 7.6% of cases. 119 
The mean GH concentration at diagnosis was 31.1 ± 37 mcg/L. The median GH was 20 mcg/L, 120 
IQR 10-36 mcg/L.  121 
Nadir GH after glucose load was reported in 861 patients; in only 3 (0.3%) it was lower than 1 122 
mcg/L. However, all these 3 patients showed typical clinical features, elevated IGF-I and a 123 
documented pituitary GH-secreting adenoma at surgery. 124 
IGF-I serum levels were available at diagnosis in 1004 patients (66.4%). The mean value was 744 125 
± 318 ng/ml. The median IGF-I as age-specific Standard Deviation Score (SDS) was 8.53 (IQR 126 
5.82-12.34); without differences between men and women being observed. 127 
Hyperprolactinemia was reported in 250/1310 patients (19%). It was observed more frequently in 128 
women than in men (65.7% vs 34.3%, P <0.001) and in macro- than in micro-adenomas (80.5% vs 129 
19.5%, P < 0.001). Nine patients had associated TSH hypersecretion and central hyperthyroidism. 130 
At diagnosis, 392 (26%) patients had one or more pituitary deficiencies: 4.1% hypoadrenalism, 131 
8.1% hypothyroidism, 16.4% hypogonadism and 0.6% diabetes insipidus. All were adequately 132 
treated. Pituitary deficiencies were equally distributed between the two genders except for 133 
hypogonadism that was more frequent in men (24.2% vs 10.9%, P< 0.0001). Smoking at the time 134 
of diagnosis was reported by 36% of patients, a share slightly greater than that reported for the 135 
general adult Italian population in the same years (about 30%) (18). 136 
 137 
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Co-morbidities: Diabetes Mellitus and Arterial Hypertension 138 
Diabetes mellitus was reported in 16.2% of cases, 139 women and 106 men with an age  139 
standardized rate of 12.4% and 16.2% respectively (P= NS). Diabetes mellitus was diagnosed at 140 
an earlier age than in the general population (Fig. 3 A,B). A multivariate analysis considering age, 141 
gender, GH and IGF-I serum levels at diagnosis, and months of delay before diagnosis showed 142 
that older age, male gender and higher IGF-I but not GH levels at diagnosis were significant 143 
predictors of diabetes (Table 1). 144 
Hypertension affected 33% of acromegalic patients and was equally distributed between women 145 
and men (age standardized rate: 33.7% vs 28.7%, respectively P= NS); however, it also appeared 146 
at younger age than in the normal population (Fig. 3 C,D). A multivariate model considering age, 147 
gender, GH and IGF-I serum levels at diagnosis, and months of delay before diagnosis showed 148 
that older age and higher IGF-I levels at diagnosis were significant predictors of hypertension 149 
(Table 1). 150 
 151 
Treatment 152 
Several treatments are used to achieve cure in acromegaly, alone or in combination (Table 2). 153 
Eigthy percent of patients underwent surgical procedures. Pharmacotherapies were used in 75% of 154 
patients. The kind of medical therapy was reported in 720 cases: 74.6% (537/720) had been treated 155 
with short or long acting somatostatin analogs (SSA), 10.3% (74/720) with the dopamine agonists 156 
(DA) bromocriptine or cabergoline, 2.9% (20/720) with GH receptor antagonist and 12.2% 157 
(88/720) with both DA and SSA either sequentially or in combination. Radiotherapy was used in 158 
18% (269/1512) of patients, with 14% of them (39/269) who received two or more cycles.  159 
Radiosurgery, mainly Gamma Knife was used in 5.6% of the patients. 160 
Only 34.4% of patients received only one kind of treatment, while 47.9% received two, 16.5% 161 
three and 1.2 % four. Patients who received only one type of treatment underwent surgery in 53% 162 
of cases, medical therapy in 46% and radiotherapy in 1%. 163 
Treatment choice was not different in patients bearing micro vs macro-adenomas and intra- vs 164 
extrasellar adenomas. 165 
Page 11 of 33
Arosio M et al   
12 
 
 166 
Disease-specific outcomes 167 
The mean GH levels at the last follow-up were 4.9 ± 15 mcg/L (median 2 mcg/L, IQR 1-3.8). In 168 
detail, GH levels decreased <2.5 mcg/L in 60.8% (below 1 mcg/L in 21.6% of the entire cohort). 169 
Among the 695 patients who underwent a glucose load after therapy, 54.4% of them showed a 170 
nadir GH <1 mcg/L. 171 
At the last follow-up, IGF-I serum levels were available in 1321 patients (87% of the overall 172 
cohort). The mean value was 293 ± 207 ng/ml and 802 patients (60.7%) achieved IGF-I levels in 173 
the normal range.  The median IGF-I SDS was 1.34 (IQR 0.11-3.50); it was significantly higher in 174 
men than in women (1.95, IQR 0.33-4.39 vs 1.11, IQR 0.04-2.80, respectively; P< 0.05). 175 
Hyperprolactinemia persisted in 6.2% patients. At the last follow-up, patients who received 176 
pituitary conventional radiotherapy were more frequently hypothyroidal, hypoadrenal and 177 
hypogonadal than patients who did not (62% vs 11%, 45% vs 10%, 57% vs 12%, P<0.001). At the 178 
last follow-up. 932/1427 patients (65%) were reported with controlled disease by the attending 179 
endocrinologist; among these, 55% (36% of the entire cohort) were off medical therapy. A 180 
recurrence after an initial remission was reported in 23 patients (2.4%). 181 
Patients who achieved disease control had undergone surgery in 86% of cases vs 69% of patients 182 
with active disease. 183 
An univariate model considering age, gender, GH and IGF-I (expressed either as SDS or absolute 184 
value) at diagnosis, extension and size of the adenoma, delay of diagnosis, diabetes, hypertension 185 
and hyperprolactinemia showed that male gender, extrasellar extension of the adenoma, highest 186 
GH levels at diagnosis and diabetes were significant independent predictors of disease activity. 187 
 188 
Mortality 189 
By the end of 2002, 61 patients had died: 4.1% of men and 3.9% of women. The average age was 190 
64 ± 12 years (median 66.5 years; IQR 53.5-70.7 years) without differences between genders. 191 
Older age, higher GH at the last follow-up, higher IGF-I levels at diagnosis, malignancy and 192 
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conventional radiotherapy were independent predictors of mortality (Table 3). Of note that 193 
superimposable results were obtained by expressing IGF-I as absolute values or as SDS. 194 
Conventional external radiotherapy was also significantly associated to an increased morbility for 195 
ischemic vascular diseases (35% in patients receiving radiotherapy vs 17% in the remainders, 196 
P<0.005), In our series, the prevalence of hypoadrenalism or hypogonadism was similar between 197 
deceased and alive patients. 198 
Main causes of death were vascular diseases and malignancies with similar prevalence. Twenty-199 
three patients died from vascular diseases, 27.9% from cardiovascular and 9.8% from 200 
cerebrovascular events. Women died more from stroke (20% vs 4%, P < 0.001) while men 201 
from heart diseases (41% vs 28%, P= NS). The prevalence of death from malignancies 202 
was 36% (22/61) with no differences between genders. The cause of death was unknown for 203 
12 patients. 204 
The expected deaths were 53, that gives a  SMR for the total cohort not significantly higher than 205 
the general Italian population (1.13; 95% CI, 0.86-1.46). SMR was 1.93 (95% CI, 1.34-2.70) in 206 
the subgroup of patients with persistently active disease as compared with 0.59 (95% CI, 0.37-207 
0.90) in the patients with controlled disease. 208 
 209 
Discussion 210 
In the present epidemiological study, the first so far in Italy and one the largest ever published, we 211 
have reported data on 1512 patients, representative of the acromegalic population in Italy. We 212 
assume to have included nearly the 45% of  all the Italian acromegalica cases of that period, 213 
considering an Italian population of 57.000.000 inhabitants in 2002 and an estimated prevalence of 214 
acromegaly of 60 per million (15). Like other retrospective studies involving a long period of 215 
time, our survey presents some difficulties in the comparison of data collected across different 216 
centres. However, this is an inevitable trade-off to have the statistical power needed to answer 217 
important epidemiological issues. 218 
The median age at diagnosis was 46 years, very similar to previous reports (11,15,19-22). In our 219 
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cohort, there was a prevalence of the female gender (59%) in agreement with most (9,21,22) even 220 
if not all cohorts (Table 4) (13,20,23,24).  221 
A higher prevalence of women was also described in one of the first epidemiological studies, 222 
published by Davidoff in 1926 (25). Both a diagnostic bias due to the greater awareness of women 223 
for their features or a real increased prevalence are possible explanations. However, it is of 224 
interest that men are more often diagnosed before the age of 45 years and women later on, as 225 
shown in Fig. 2, and in agreement with other series (21). Thus, a protective role of estrogen, 226 
delaying clinical presentation of acromegaly during the reproductive period could be 227 
hypothesized, since it is well known that estrogen reduces IGF-I concentrations in both normal 228 
and acromegalic women (26-29). 229 
The mean delay in diagnosis was 6 years similar to that reported in most recent series 230 
(13,21,22,30). The delay in diagnosis was 10-20 years in the sixties (31), 9 years in the eighties 231 
(23), and 6 years in the nineties, but in the last 20 years it does not seem to be shortened further 232 
(21); thus, acromegaly remains an underestimated disease (30-33). 233 
It is well known that the prevalence of diabetes mellitus and hypertension are higher in 234 
acromegalic patients than in the general population. In our cohort, diabetes mellitus was reported 235 
in 16% of cases, with respect to 4.5% of the Italian population. However, we cannot exclude to 236 
have underestimated the real prevalence of the condition due to the retrospective nature of 237 
our study and since an oral glucose load was missing in a number of patients. As in the 238 
general population, the prevalence of diabetes increased with age, but starting at a younger age. In 239 
literature, the prevalence of diabetes mellitus varies across a wide range, from 9% to 40% (Table 240 
4) (8,15,19,22). Besides differences due to genetic background, nutritional habits, age, BMI and 241 
referral pattern, it has to be considered that diagnostic criteria have been revised in the nineties 242 
making comparisons even more difficult. We confirmed that older age is an independent predictor 243 
of diabetes (22,23), while higher GH levels and delay of diagnosis were not, at variance with some 244 
previous observations (23). In addition, male gender appeared to be at greater risk of developing 245 
diabetes mellitus whereas no gender-related difference is evident in the general Italian population. 246 
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It is remarkable that only IGF-I levels at diagnosis, and not GH, predicted the presence of 247 
diabetes. This is intriguing, considering both old studies in which IGF-I levels often reflected 248 
elevated fasting blood glucose in acromegaly (34) and very recent epidemiological studies 249 
showing that in the general population subjects with IGF-I levels in the upper normal range are at 250 
increasing risk of developing diabetes mellitus (35). 251 
Also the prevalence of hypertension varied remarkably across previous studies, from 18% to 60% 252 
(Table 4) with a mean prevalence of about 34% in a review collecting more than 2500 cases (36). 253 
Differences in diagnostic criteria and in techniques of blood pressure recording may explain most 254 
of the variability. In our series hypertension was found in 33% of patients, in comparison to 13.6% 255 
of the background population matched for gender and age. As in the general population, no gender 256 
difference was observed and the prevalence increased with age, so that nearby 50% of the 257 
acromegalic patients older than 55 years were hypertensive (Fig. 3 C,D), both findings being 258 
consistent with previous observations (37). We also confirmed that hypertension, like diabetes, in 259 
the acromegalic population occurs not only more frequently, but also earlier than in the general 260 
population. While higher GH levels at baseline were not an independent predictor of hypertension, 261 
IGF-I levels were, in keeping with a previous study (38). It is noteworthy that IGF-I has been 262 
implicated in the pathogenesis of essential hypertension (37,39), even if the mechanisms involved 263 
are still not clarified (37). To further underline the importance of IGF-I in the development of co-264 
morbidities in acromegaly, as suggested by the pioneering work of Clemmons (34), a recent paper 265 
showed that IGF-I normalization by pegvisomant resulted in a significant improvement of either 266 
hypertension or diabetes mellitus (40). 267 
Treatment approach obviously changed during the long study period. In particular, medical 268 
therapies and radiosurgery became more frequent starting to mid-nineties while conventional 269 
radiotherapy became progressively less used (11,20). Most of our patients (80%) underwent 270 
surgery at some time, a figure similar to several studies (11,13,19,21,24). 271 
Pharmacotherapy was used in about three-quarters of our patients while radiotherapy and 272 
radiosurgery in 23% of cases, similarly to other series (20-21,24). Surprisingly, in our population 273 
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there were no differences in the choice of first line treatment on the basis of tumor size and 274 
extension; indeed, first-line treatment was surgical in 53.3% and medical in 45.9% of cases. To 275 
have a comparison with recent surveys, in the Belgian registry (20) primary medical therapy was 276 
used in 23% and in the German registry in 34% (21). 277 
In our series, 65% of patients were considered in remission at the last follow-up. This figure 278 
reflects the results of years in which GH-antagonist was not yet available, but somatostatin 279 
analogs had already entered clinical practice, and is comparable or even higher than other 280 
databases. The global cure or control rate reported in the Belgian (20) and in the West Midlands 281 
(9) databases were 49% and 46%, respectively. In Spanish register, cure was reported in 31% (19) 282 
and in the Finnish database, either GH<2.5 mcg/L or normal IGF-I was achieved by 55% of 283 
patients (11) (Table 4). As expected, however, these figures are lower than those reported by single 284 
centres of excellence (10). We observed that male patients with extrasellar adenoma, higher GH 285 
levels at diagnosis and diabetes had the lowest probability of achieving control of their disease, all 286 
these factors being independent predictors. 287 
It is well known that untreated acromegaly is associated with a decreased life expectancy (4). In 288 
our series, 61 patients (4%) died during 10 year follow-up, compared with 53 expected, without 289 
differences between genders, at variance with other groups of patients with pituitary 290 
diseases. For example among patients with hypopituitarism the mortality is greater in women (4).  291 
The median age of death of our series (66 year) is similar to what reported by other European 292 
studies (9,11,20).  In the total cohort the mortality for all causes was not significantly higher than 293 
in the general Italian population, while in the subgroup of patients who did not achieve full 294 
hormonal control it was increased by about 2-fold. These findings are in agreement with most 295 
(4,8,10,19), even if not all (7, 13) recent series (Table 4). They confirm that the excess mortality 296 
associated with acromegaly can be greatly reduced by the modern management of the disease, that 297 
is able to successfully control hormonal hypersecretion in the majority of the patients. However, it 298 
has to be considered that an analysis of mortality in these cohorts, including ours, is complex 299 
due to the low number of deaths by epidemiological standards (4) and the presence of other 300 
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confounding factors such as the year of publication and differences among the populations of 301 
reference. In addition, due to the fact that only tertiary referral centres participated to the survey, 302 
mortality and morbidity rate were probably underestimated compared to the general Italian 303 
acromegalica population. 304 
As in the general population, the main causes of death were found to be vascular diseases and 305 
malignancies. The reported prevalence of cerebrovascular death in acromegalic patients ranged 306 
from 12% to 21% in the different series  (7,9,19,20), while in our population it occurred only in 307 
9.8% of cases, mostly in female. The lower figure may be due to a limited use of conventional 308 
radiotherapy with respect to the oldest series. Cardiovascular death rate (27.8%) is comparable to 309 
data reported in Spanish (19) and Belgian registers (20), but is lower than in other European 310 
studies (1,7,9), and this likely reflects the lower cardiovascular mortality of the respective general 311 
populations (41). Conversely, death from malignancies(36%) was more frequent than that 312 
reported by other European surveys (7,19,20), and deserves further investigation. 313 
Besides age at diagnosis and development of malignancy during follow-up, conventional 314 
radiotherapy (not including radiosurgery) and the last known GH value at follow-up were 315 
independent predictors of mortality, in keeping with other series (4,9,11). It may be expected that 316 
the new conformational techniques of radiotherapy could be less dangerous; however, the number 317 
of patients who underwent radiosurgery was too small to provide useful information about the 318 
possible link between this kind of therapy and survival. Hypertension and diabetes mellitus were 319 
significant predictors of mortality only in univariate but not in multivariate analysis, in keeping 320 
with the original study by Bates (6). This may be due to their tight correlation with age and IGF-I 321 
level at diagnosis. Interestingly, high IGF-I level at diagnosis was an independent predictor of 322 
mortality, whereas both basal GH concentrations and the last IGF-I concentrations were not. In 323 
this context, it is worth recalling that in the eighties IGF-I levels were considered by many experts 324 
the best marker of severity of the acromegalic disease (34). A strength of our study is the large 325 
number of acromegalic patients in whom IGF-I levels were available at diagnosis and this may 326 
explain why previous studies including a limited data set were not able to demonstrate a predictive 327 
Page 17 of 33
Arosio M et al   
18 
 
role for IGF-I (1,3,6-10,13). The limitation that IGF-I levels have been measured by different 328 
assays was circumvented by comparing them with those of the largest Italian database, the one of 329 
the University of Genoa, thus allowing to express IGF-I also as SDS in the statistical analysis. 330 
Since we have obtained superimposable results with rough values or SDS, we think that our 331 
conclusions are not significantly affected by this limitation. 332 
In conclusion, we have confirmed that diabetes mellitus and hypertension are more frequent and 333 
peak much earlier in acromegaly than in the background population. We have shown that male 334 
patients with extrasellar adenomas, high GH levels at diagnosis and diabetes mellitus have the 335 
lowest probability of achieving control of their disease. We have confirmed the deleterious effects 336 
of conventional radiotherapy and the lack of a complete control of GH hypersecretion, but also 337 
shown that modern management of the disease is associated with an almost normal life span. 338 
However, we have not been able to confirm that the last known IGF-I level is an independent 339 
predictor of mortality, while we have shown for the first time the importance of IGF-I levels at 340 
diagnosis in causing morbidity and long-term mortality. 341 
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Figure legends: 
Figure 1: Percentage distribution of patients throughout Italy 
Figure 2: Distribution of acromegalic patients according to gender (males: closed bars, females: open 
bars) and age group at diagnosis 
Figure 3: Percentage prevalence of diabetes mellitus (A) and hypertension (C) in the acromegalic 
population in respect to the Italian general population (B,D) according to age groups and gender 
(males: closed bars, females: open bars) 
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Table 1 Predictors of diabetes mellitus and hypertension (multivariate analysis) 
 Diabetes Mellitus Hypertension 
Variables OR 95% CI P value OR 95% CI P value 
Age 2.26 1.68-3.05 0.001 2.84 2.32-3.48 0.001 
Male sex 1.64 1.08-2.52 0.02 0.85 0.65-1.11 NS 
GH at diagnosis 0.99 0.95-1.03 NS 0.97 0.91-1.03 NS 
IGF-I at diagnosis (SDS) 1.11 1.00-1.24 0.05 1.50 1.12-2.01 0.02 
Delay of diagnosis 1.14 0.92-1.41 NS 0.86 0.74-1.01 0.05 
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Table 2 Distribution of treatments modalities 
 
Therapies Patients n (%) 
Surgery 1222 (80)  
        Surgery alone      262 (21.5) 
        In combination with pharmacotherapy         651 (53.3) 
        In combination with radiotherapy or radiosurgery  38 (3) / 10 (0.8) 
        In combination with two or more therapies  261 (21.4) 
Pharmacotherapy 1147 (75)  
        Pharmacotherapy alone  203 (17.7) 
        In combination with radiotherapy or radiosurgery  23 (2) / 2 (0.2) 
        In combination with two or more therapies  919 (80.1) 
Radiotherapy  269 (18)  
        Radiotherapy alone           4 (1.5) 
        Radiotherapy in combination  265 (98.5) 
Radiosurgery 85 (5.6)  
        Radiosurgery alone  0 (0) 
        Radiosurgery in combination              85 (100) 
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Table 3 Predictors of mortality  
Variables OR 95% CI P value 
Univariate model    
Age 3.55 2.42-5.21 <0.001 
Male sex 1.06 0.63-1.78 NS 
Macroadenoma 0.85 0.47-1.54 NS 
Delay of diagnosis 1.29 0.98-1.69 NS 
GH at diagnosis 1.02 1.00-1.04 NS 
IGF-I at diagnosis (SDS) 1.12 1.00-1.25 0.05 
GH at FU 1.03 1.00-1.06 0.05 
IGF-I at FU (SDS) 0.99 0.82-1.21 NS 
Malignancy 11.98 6.95-20.64 <0.001 
Diabetes 1.09 1.02-3.51 0.04 
Hypertension 2.29 1.37-3.83 0.002 
Radiotherapy 2.35 1.36-4.09 0.002 
Hypoadrenalism 0.51 0.07-3.79 NS 
Hypogonadism 1.15 0.55-2.41 NS 
N° of therapies 0.51 0.27-0.99 NS 
Smoking 1.44 0.72-2.85 NS 
Multivariate model    
Age 4.58 2.62-7.99 <0.001 
IGF-I at diagnosis (SDS) 1.14 1.01-0.25 0.04 
GH at FU 1.06 1.03-1.10 <0.001 
Malignancy 7.26 3.54-14.86 <0.001 
Diabetes 0.87 0.37-2.06 NS 
Hypertension 0.81 0.40-1.65 NS 
Radiotherapy 4.32 1.97-9.45 <0.001 
 
Page 28 of 33
Table 4. European Registers 
 
Patients 
n°(M/F) 
Age at 
diagnosis 
mean (M/F) 
Macro-
adenomas 
(%) 
Diabetes 
Mellitus 
(%) 
Hypertension 
(%) 
Disease 
control 
(%) 
SMR  
(IC 95%) 
Ayuk et al, 2004 (9) 419 (178/241) 47 - - - 46 1.26 (1.03-1.54) 
Mestron et al, 2004 (19) 1219 (478/741) 45 73 37.6 39.1 31 - 
Holdaway et al, 2004 (13) 208 (125/83) 42 84 53 60 - 2.70 (2.10-3.50) 
Kauppinen-Makelin et al, 2005 (11) 334 (161/173) 47.5 (45/49) 67 - - 55 1.16 (0.85-1.54) 
Bex et al, 2007 (20) 418 (213/205) 44 (42/46) 79 25.3 39.4 49 1.39 (0.96-2.03) 
Petersenn et al, 2009 (21) 1485 (677/808) 44 (41/47) 79 - - - - 
Present Study 1512 (624/888) 45 (43/47) 70 16 33 65 1.13 (0.87-1.46) 
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